home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
TIME: Almanac 1990s
/
Time_Almanac_1990s_SoftKey_1994.iso
/
time
/
061890
/
0618620.000
< prev
next >
Wrap
Text File
|
1993-04-15
|
3KB
|
64 lines
<text id=90TT1619>
<link 89TT3040>
<title>
June 18, 1990: New Hope For Alzheimer's Victims
</title>
<history>
TIME--The Weekly Newsmagazine--1990
June 18, 1990 Child Warriors
</history>
<article>
<source>Time Magazine</source>
<hdr>
ETHICS, Page 70
New Hope for Alzheimer's Victims
</hdr>
<body>
<p> Even as Janet Adkins committed suicide, the short history
of Alzheimer's disease seemed to be entering a new, more
hopeful phase. First, it will soon be easier to identify
Alzheimer's earlier and more accurately, thus easing the
needless anxiety the elderly often feel at any lapse of memory
or momentary confusion. (Doctors admit that their diagnoses of
the disease are wrong about 30% of the time.) Second,
Alzheimer's finally appears to be yielding to treatment, though
a cure could be many years away.
</p>
<p> Last week researchers at Abbott Laboratories near Chicago
announced they had developed a new biochemical test that may
prove to be highly reliable in detecting a collection of
molecules, called Alzheimer's disease-associated proteins
(ADAP), found in substantial quantities only in patients with
the illness.
</p>
<p> In an article published in the Journal of the American
Medical Association, investigators from Abbott and seven other
research centers in the U.S. and Europe reported the results
of tests of 111 samples of brain tissue taken from people who
had recently died. Some suffered from Alzheimer's, some had
other neurological disorders, and the rest died from unrelated
causes. Using a simple procedure involving common laboratory
techniques, the scientists were able to identify 86% of the
patients who had been stricken with Alzheimer's. The scientists
expect that within two years they will be able to develop a
similar test that would detect ADAP in spinal fluid taken from
living patients.
</p>
<p> Early diagnosis will be increasingly important as new
treatments for Alzheimer's become available. Drug companies are
testing more than 100 compounds that may at least relieve or
delay the symptoms of the illness. Last week Warner-Lambert,
a New Jersey pharmaceutical firm, applied for Government
permission to market Cognex, a brand of tacrine, a drug that
supposedly slows the loss of brain function in 40% of
Alzheimer's patients who are given the medication. Such a drug,
along with the new test to detect the disease, could conceivably
add one or more productive years to the lives of Alzheimer's
victims.
</p>
</body>
</article>
</text>